a close up of a red and blue substancePhoto by CDC

July 02 2024 12:03:54 — Fresenius Kabi launches subcutaneous Tyenne® (tocilizumab-aazg) in the U.S., enhancing affordable chronic autoimmune disease treatments and advancing its (Bio)Pharma momentum.

Tyenne is the company’s third biosimilar in the U.S., previously launched in an intravenous form.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner